Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kadmon announces expanded results of interim analysis of KD025 trial in cGVHD » 16:05
02/23/20
02/23
16:05
02/23/20
16:05
KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

Kadmon announced expanded…

Kadmon announced expanded results from the previously reported interim analysis of ROCKstar, its ongoing pivotal trial of KD025 in chronic graft-versus-host disease. As announced in November 2019, KD025 met the primary endpoint of Overall Response Rate at the study's planned interim analysis, two months after completion of enrollment. KD025 showed statistically significant and clinically meaningful ORRs of 64% with KD025 200 mg once daily and 67% with KD025 200 mg twice daily. In the expanded KD025-213 dataset presented, ORRs were consistent with the previously reported interim analysis across key subgroups, including in patients with four or more organs affected by cGVHD, patients who had prior treatment with ibrutinib and patients who had prior treatment with ruxolitinib. Three patients achieved a Complete Response. Responses were observed in all affected organ systems, including in organs with fibrotic disease. KD025 has been well tolerated: adverse events were consistent overall with those expected to be observed in cGVHD patients receiving corticosteroids, and no apparent increased risk of infection was observed. Additional secondary endpoints, including duration of response, corticosteroid dose reductions, Failure-Free Survival, Overall Survival and Lee Symptom Scale reductions continue to mature and will be available later in 2020. At the TCT Meetings, Kadmon also presented long-term follow-up data from KD025-208, its ongoing Phase 2 study of KD025 in cGVHD. These data were recently presented at the 61st American Society of Hematology Annual Meeting and Exposition in December 2019.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/23/20
02/23
04:55
02/23/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Saturday
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/22/20
02/22
04:55
02/22/20
04:55
ABBV

AbbVie

$94.96 /

+0.7 (+0.74%)

, ADPT

Adaptive Biotechnologies

$34.19 /

+0.37 (+1.09%)

, AMGN

Amgen

$222.80 /

+0.62 (+0.28%)

, ATNM

Actinium Pharmaceuticals

$0.26 /

+0.0088 (+3.50%)

, ATRA

Atara Biotherapeutics

$13.18 /

-0.34 (-2.51%)

, AZN

AstraZeneca

$50.17 /

+1.2 (+2.45%)

, BLUE

Bluebird Bio

$80.15 /

-2.38 (-2.88%)

, CDNA

CareDx

$28.25 /

+0.13 (+0.46%)

, CDTX

Cidara Therapeutics

$3.16 /

+ (+0.00%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.48 /

+0.38 (+7.45%)

, GMDA

Gamida Cell

$4.55 /

-0.2 (-4.21%)

, GSK

GlaxoSmithKline

$43.11 /

+0.35 (+0.82%)

, HUM

Humana

$369.65 /

-1.9 (-0.51%)

, INCY

Incyte

$80.89 /

-1.88 (-2.27%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.08 /

+0.03 (+0.59%)

, MGTA

Magenta Therapeutics

$14.00 /

-0.02 (-0.14%)

, MRK

Merck

$82.34 /

-0.14 (-0.17%)

, NVS

Novartis

$96.75 /

+0.44 (+0.46%)

, PFE

Pfizer

$35.71 /

-0.13 (-0.36%)

, RCKT

Rocket Pharmaceuticals

$22.73 /

-1.01 (-4.25%)

, SGEN

Seattle Genetics

$117.00 /

-1.3 (-1.10%)

, SNY

Sanofi

$50.83 /

+0.07 (+0.14%)

, TAK

Takeda Pharmaceutical

$18.78 /

+0.195 (+1.05%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Friday
Recommendations
BioMarin price target raised to $175 from $158 at Wedbush » 12:22
02/21/20
02/21
12:22
02/21/20
12:22
BMRN

BioMarin

$94.39 /

+4.73 (+5.28%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos raised her price target on BioMarin to $175 from $158 and maintained an Outperform rating.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/21/20
02/21
04:55
02/21/20
04:55
ABBV

AbbVie

$94.26 /

+0.13 (+0.14%)

, ADPT

Adaptive Biotechnologies

$33.82 /

+0.28 (+0.83%)

, AMGN

Amgen

$222.18 /

-0.94 (-0.42%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0011 (+0.44%)

, ATRA

Atara Biotherapeutics

$13.52 /

-1.23 (-8.34%)

, AZN

AstraZeneca

$48.97 /

-0.34 (-0.69%)

, BLUE

Bluebird Bio

$82.53 /

+1.98 (+2.46%)

, CDNA

CareDx

$28.12 /

-0.05 (-0.18%)

, CDTX

Cidara Therapeutics

$3.16 /

-0.01 (-0.32%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.10 /

+0.04 (+0.79%)

, GMDA

Gamida Cell

$4.75 /

+ (+0.00%)

, GSK

GlaxoSmithKline

$42.76 /

+0.4688 (+1.11%)

, HUM

Humana

$371.55 /

-7.115 (-1.88%)

, INCY

Incyte

$82.77 /

+0.32 (+0.39%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.05 /

-0.085 (-1.66%)

, MGTA

Magenta Therapeutics

$14.02 /

+0.91 (+6.94%)

, MRK

Merck

$82.48 /

+0.48 (+0.59%)

, NVS

Novartis

$96.31 /

-0.98 (-1.01%)

, PFE

Pfizer

$35.84 /

-0.39 (-1.08%)

, RCKT

Rocket Pharmaceuticals

$23.74 /

-0.26 (-1.08%)

, SGEN

Seattle Genetics

$118.30 /

-1.6 (-1.33%)

, SNY

Sanofi

$50.76 /

+0.06 (+0.12%)

, TAK

Takeda Pharmaceutical

$18.59 /

-0.43 (-2.26%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Hot Stocks
BioMarin: FDA accepts for priority review BLA for valoctocogene roxaparvovec » 16:33
02/20/20
02/20
16:33
02/20/20
16:33
BMRN

BioMarin

$89.66 /

-0.19 (-0.21%)

BioMarin announced that…

BioMarin announced that the U.S. FDA has accepted for Priority Review the Biologics License Application to the FDA for its investigational AAV5 gene therapy, valoctocogene roxaparvovec, for adults with hemophilia A. This acceptance by the FDA marks the first marketing application accepted for a gene therapy product for any type of hemophilia in the United States. The FDA has granted priority review designation to valoctocogene roxaparvovec, which is granted to drugs that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. The Prescription Drug User Fee Act action date is August 21, 2020. The FDA has informed the company that they are not currently planning to hold an advisory committee meeting to discuss the application .

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
TG Therapeutics put volume heavy and directionally bearish » 13:15
02/20/20
02/20
13:15
02/20/20
13:15
TGTX

TG Therapeutics

$15.75 /

-0.25 (-1.56%)

Bearish flow noted in TG…

Bearish flow noted in TG Therapeutics with 2,696 puts trading, or 5x expected. Most active are Mar-20 10 puts and Mar-20 16 puts, with total volume in those strikes near 2,200 contracts. The Put/Call Ratio is 1.61, while ATM IV is up over 5 points on the day. Earnings are expected on February 28th.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 04:55
02/20/20
02/20
04:55
02/20/20
04:55
ABBV

AbbVie

$94.13 /

+0.53 (+0.57%)

, ADPT

Adaptive Biotechnologies

$33.54 /

+1.79 (+5.64%)

, AMGN

Amgen

$223.12 /

+1.38 (+0.62%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

+0.0041 (+1.67%)

, ATRA

Atara Biotherapeutics

$14.75 /

+0.2 (+1.37%)

, AZN

AstraZeneca

$49.31 /

+0.14 (+0.28%)

, BLUE

Bluebird Bio

$80.55 /

-7.61 (-8.63%)

, CDNA

CareDx

$28.17 /

+1.02 (+3.76%)

, CDTX

Cidara Therapeutics

$3.17 /

+0.09 (+2.92%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.06 /

+0.02 (+0.40%)

, GMDA

Gamida Cell

$4.75 /

-0.01 (-0.21%)

, GSK

GlaxoSmithKline

$43.49 /

-0.06 (-0.14%)

, HUM

Humana

$378.67 /

+6.41 (+1.72%)

, INCY

Incyte

$82.45 /

+3.2 (+4.04%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$5.13 /

+0.285 (+5.88%)

, MGTA

Magenta Therapeutics

$13.11 /

+0.55 (+4.38%)

, MRK

Merck

$82.00 /

-0.46 (-0.56%)

, NVS

Novartis

$97.29 /

+0.08 (+0.08%)

, PFE

Pfizer

$36.23 /

-0.08 (-0.22%)

, RCKT

Rocket Pharmaceuticals

$24.00 /

-1.18 (-4.69%)

, SGEN

Seattle Genetics

$119.90 /

-0.09 (-0.08%)

, SNY

Sanofi

$50.70 /

-0.44 (-0.86%)

, TAK

Takeda Pharmaceutical

$19.02 /

-0.135 (-0.70%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Conference/Events
The ASTCT and CIBMTR to hold a joint meeting » 08:09
02/19/20
02/19
08:09
02/19/20
08:09
ABBV

AbbVie

$93.60 /

-0.47 (-0.50%)

, ADPT

Adaptive Biotechnologies

$31.75 /

+0.29 (+0.92%)

, AMGN

Amgen

$221.74 /

-1.58 (-0.71%)

, ATNM

Actinium Pharmaceuticals

$0.25 /

-0.0132 (-5.09%)

, ATRA

Atara Biotherapeutics

$14.55 /

+0.3 (+2.11%)

, AZN

AstraZeneca

$49.17 /

+1.3 (+2.72%)

, BLUE

Bluebird Bio

$88.16 /

-0.98 (-1.10%)

, CDNA

CareDx

$27.15 /

+0.48 (+1.80%)

, CDTX

Cidara Therapeutics

$3.08 /

+0.1 (+3.36%)

, CELG

Bought by BMY

$0.00 /

+ (+0.00%)

, EQ

Equillium

$5.04 /

+0.06 (+1.20%)

, GMDA

Gamida Cell

$4.76 /

+0.035 (+0.74%)

, GSK

GlaxoSmithKline

$43.55 /

-0.19 (-0.43%)

, HUM

Humana

$372.26 /

-3.815 (-1.01%)

, INCY

Incyte

$79.25 /

+0.83 (+1.06%)

, JAZ

Jazz Technologies

$0.00 /

+ (+0.00%)

, KDMN

Kadmon

$4.85 /

+0.325 (+7.19%)

, MGTA

Magenta Therapeutics

$12.56 /

+0.2 (+1.62%)

, MRK

Merck

$82.46 /

-0.18 (-0.22%)

, NVS

Novartis

$97.21 /

-0.465 (-0.48%)

, PFE

Pfizer

$36.31 /

-0.18 (-0.49%)

, RCKT

Rocket Pharmaceuticals

$25.18 /

+1.18 (+4.92%)

, SGEN

Seattle Genetics

$119.99 /

+1.9 (+1.61%)

, SNY

Sanofi

$51.14 /

+1.21 (+2.42%)

, TAK

Takeda Pharmaceutical

$19.15 /

-0.29 (-1.49%)

American Society for…

American Society for Transplantation & Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) hold the 2020 TCT: Transplantation & Cellular Therapy Meeting will be held in Orlando on February 19-23.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Tuesday
Recommendations
'Not a bad start' for Mustang Bio's MB-106 news, says H.C. Wainwright » 11:25
02/18/20
02/18
11:25
02/18/20
11:25
MBIO

Mustang Bio

$3.74 /

-0.015 (-0.40%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis notes that Mustang Bio announced that its drug candidate MB-106 scored the first complete response in the first patient treated in the ongoing MB-106 Phase 1/2 trial. The analyst also points out that "this encouraging first clinical win" was observed following 28 days, after one single low dose of CARs and with no toxicity, such as cytokine release syndrome and neurotoxicity. Pantginis expects to see follow-up data of the trial at upcoming meetings, likely at ASH, by year-end 2020. The analyst has a Buy rating and $7 price target on the shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.